文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights from the PEGASUS-TIMI 54 Trial.

作者信息

Patel Siddharth M, Bonaca Marc P, Morrow David A, Palazzolo Michael G, Jarolim Petr, Steg Philippe Gabriel, Bhatt Deepak L, Storey Robert F, Sabatine Marc S, O'Donoghue Michelle L

机构信息

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

University of Colorado School of Medicine, Aurora, CO.

出版信息

JACC Adv. 2023 Nov;2(9). doi: 10.1016/j.jacadv.2023.100675. Epub 2023 Oct 28.

DOI:10.1016/j.jacadv.2023.100675
PMID:38106527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10723808/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ad/11198547/a96c32872652/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ad/11198547/a96c32872652/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ad/11198547/a96c32872652/gr1.jpg

相似文献

[1]
Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights from the PEGASUS-TIMI 54 Trial.

JACC Adv. 2023-11

[2]
Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria.

Front Cardiovasc Med. 2022-11-17

[3]
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.

Eur Heart J. 2015-10-21

[4]
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.

Eur Heart J. 2020-5-1

[5]
Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry.

BMC Cardiovasc Disord. 2021-3-18

[6]
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.

Heart. 2016-5-15

[7]
Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy.

Rev Esp Cardiol (Engl Ed). 2016-5

[8]
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.

Am Heart J. 2014-1-6

[9]
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial.

J Am Heart Assoc. 2021-9-7

[10]
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).

Circulation. 2016-8-30

引用本文的文献

[1]
The challenge of secondary cardiovascular prevention in very high Lipoprotein (a) level: a case report.

Eur Heart J Case Rep. 2025-8-9

[2]
2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.

Arch Med Sci. 2025-2-22

[3]
Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening.

Am J Prev Cardiol. 2025-2-14

[4]
Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk.

Eur Heart J Open. 2024-8-31

[5]
Strategies for management of patients with elevated lipoprotein(a).

Curr Opin Lipidol. 2024-10-1

[6]
Small apolipoprotein(a) isoforms may predict primary patency following peripheral arterial revascularization.

JVS Vasc Sci. 2024-6-11

[7]
Lipoprotein(a): Emerging insights and therapeutics.

Am J Prev Cardiol. 2024-3-29

[8]
Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.

J Am Coll Cardiol. 2024-3-5

本文引用的文献

[1]
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes.

J Am Coll Cardiol. 2022-10-4

[2]
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.

Eur Heart J. 2022-10-14

[3]
Long-term use of ticagrelor in patients with prior myocardial infarction.

N Engl J Med. 2015-3-14

[4]
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.

Atherosclerosis. 2009-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索